R&D programs > Drug discovery

Drug discovery

Naicons’ internal discovery programs focus on discovering and developing novel bioactive compounds from our strain collection. These programs include acquired assets, which are available for licensing, and earlier drug discovery programs aiming to identify novel classes of antibacterial compounds effective against multidrug resistant bacterial pathogens. Some of the compounds we’ve discovered and our research programs are listed below.

NAI-112

A lanthipeptide, produced by Actinoplanes DSMZ24059, with efficacy in animal models of nociceptic and inflammatory pain. Likely to act through the vanilloid pathway by a novel target. It can be developed for the systemic treatment of neuropathic pain. As it’s outside Naicons' area of expertise, the compound is available for licensing.

PUM (Pseudouridimycin)

A novel class of RNA polymerase inhibitors, produced by several Streptomyces, with extremely low frequency of resistance selection. Active against Gram-positive and Gram-negative pathogens, including antibiotic-resistant isolates, with efficacy in animal models of infection. Program is under the hit-to-lead stage and available for co-development.

Other leads

Several structurally unique compounds have been identified by Naicons and are under evaluation for further development. Published compounds include: Antibacterial Paramagnetic Quinones and Allocyclinones from Actinoallomurus; NAI-802, a variant of actagardine with improved antibacterial activity; orthoformimycin, a structurally and mechanistically unusual inhibitor of bacterial protein synthesis. Other structurally unique compounds have not yet been disclosed.

C-diff

A program aimed at identifying compounds highly-active against Clostridium difficile with minimal disturbance of gut flora. In-vitro proof-of-concept has been established. Program is under the hit-to-lead stage and available for co-development.

Gram negatives

A program aimed at identifying novel classes of compounds with activity against MDR Gram-negative pathogens from WHO priority list. It employs innovative assays to screen microbial extracts from our strain collection together with a proprietary dereplication approach to quickly identify promising leads.

 
CONTACT US